As these SMPD1 inhibiting drugs are FDA-approved drug, which are frequently prescribed for neurological disorders, observational studies in well-defined patients could unravel, whether FIASMA use is associated with reduced liver injury in patients with sepsis. The gene discussed is SMPD1; the disease is Sepsis.